Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Moodys
Medtronic
AstraZeneca
Baxter

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Litigation Details for Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Docket   Start Trial Date Filed 2017-12-07
Court District Court, D. Delaware Date Terminated 2019-01-14
Cause 35:271 Patent Infringement Assigned To William C. Bryson
Jury Demand None Referred To Mary Pat Thynge
Parties CHIESI FARMACEUTICI S.P.A.; CHIESI U.S.A., INC.; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patents 6,987,094; 7,696,178; 7,939,502
Attorneys Allan A. Kassenoff; Angus Chen; Brian J. Prew; David M. Fry; Edgar H. Haug; Frederick L. Cottrell , III; Jason A. Kanter; Johnathan D. Ball; Joshua L. Raskin; Karen Elizabeth Keller; Katherine A. Daniel; Nathan Roger Hoeschen; Nicole Kathleen Pedi; Richard C. Pettus; Scaccia Giancarlo; Scott J. Bornstein
Firms Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 United States Patent Nos. 6,987,094 (“the ’094 patent”), 7,696,178 (“the ’178 patent”), and 7,939,502… This is a civil action for patent infringement arising under the patent laws of the United States, …’502 patent”), attached hereto as Exhibits A, B, and C, respectively (collectively, “the patents-in-suit…Farmaceutici S.p.A. owns the ’094 patent. 28. The ’178 patent, entitled “Optimized Formulation…Farmaceutici S.p.A. owns the ’178 patent. 29. The ’502 patent, entitled “Optimized Formulation External link to document
0000-00-00 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,987,094; 7,696,178; 7,939,502…2017 14 January 2019 1:17-cv-01772 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 95 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,987,094; 7,696,178; 7,939,502…2017 14 January 2019 1:17-cv-01772 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Colorcon
Moodys
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.